TY - JOUR
T1 - Risk Awareness and Demographic Characteristics Associated With the Use of Sexual Enhancement Supplements Among University Staff
T2 - A Cross-Sectional Study in the United Arab Emirates
AU - Jairoun, Ammar Abdulrahman
AU - Saleh Al-Hemyari, Sabaa
AU - Shahwan, Moyad
AU - Saeed, Balsam Qubais
AU - Godman, Brian
AU - Kurdi, Amanj
AU - Zyoud, Samer H.
AU - Ibrahim, Baharudin
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase in adverse effects and drug–drug interactions which cannot be avoided. Consequently, there is a need to evaluate the public risk awareness toward SES and the associated adverse events as well as explore significant factors associated with knowledge and risk awareness. A cross-sectional community-based study was conducted among University male students and staff at Ajman University, United Arab Emirates (UAE), using a self-administered survey via a web-based electronic link to explore key issues. A total of 1,101 male subjects participated in the study and completed the questionnaire. Four hundred and thirty-three(39.3%) (95% confidence interval [CI]: 33.2–44.5) participants reported using SES products. Of these, 137 (31.6%) [95% CI: 28.6–37.2] experienced adverse effects from SES product use. SES use was more prevalent among participants aged 60 to 69 years (odds ratio [OR]: 2.94; 95% CI: 1.63–5.28), diabetic patients (OR: 2.61; 95% CI: 1.75–3.90), hypertension patients (OR: 2.12; 95% CI: 1.45–3.1), and those overweight or obese (OR: 1.84; 95% CI: 1.44–2.35). This study indicates that SES is a popular practice among the UAE university staff and students. However, there is a need to implement risk awareness programs to raise public awareness regarding SES use and safety. Regulatory bodies are encouraged to provide additional advice on the proper use and possible risks of consuming SES.
AB - Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase in adverse effects and drug–drug interactions which cannot be avoided. Consequently, there is a need to evaluate the public risk awareness toward SES and the associated adverse events as well as explore significant factors associated with knowledge and risk awareness. A cross-sectional community-based study was conducted among University male students and staff at Ajman University, United Arab Emirates (UAE), using a self-administered survey via a web-based electronic link to explore key issues. A total of 1,101 male subjects participated in the study and completed the questionnaire. Four hundred and thirty-three(39.3%) (95% confidence interval [CI]: 33.2–44.5) participants reported using SES products. Of these, 137 (31.6%) [95% CI: 28.6–37.2] experienced adverse effects from SES product use. SES use was more prevalent among participants aged 60 to 69 years (odds ratio [OR]: 2.94; 95% CI: 1.63–5.28), diabetic patients (OR: 2.61; 95% CI: 1.75–3.90), hypertension patients (OR: 2.12; 95% CI: 1.45–3.1), and those overweight or obese (OR: 1.84; 95% CI: 1.44–2.35). This study indicates that SES is a popular practice among the UAE university staff and students. However, there is a need to implement risk awareness programs to raise public awareness regarding SES use and safety. Regulatory bodies are encouraged to provide additional advice on the proper use and possible risks of consuming SES.
KW - UAE
KW - erectile dysfunction
KW - risk awareness
KW - sexual enhancement supplement
KW - side effects
UR - http://www.scopus.com/inward/record.url?scp=85151111751&partnerID=8YFLogxK
U2 - 10.1177/15579883231158531
DO - 10.1177/15579883231158531
M3 - Article
C2 - 36987378
AN - SCOPUS:85151111751
SN - 1557-9883
VL - 17
JO - American Journal of Men's Health
JF - American Journal of Men's Health
IS - 2
ER -